Given our observation of increased ACE2 gene expression in patients with high SARS-CoV-2 viral load, we investigated the interplay of receiving pharmacologic angiotensin converting enzyme inhibition (ACEI) or angiotensin receptor blockers (ARBs) for hypertension and clinical features of COVID-19. Here, ACE2 is linked to hypertensive disorder.